Boardroom Alpha
Boardroom Alpha
JBIO · Additional Proxy Materials (DEFA14A) · Filed June 5, 2026

Jade Biosciences Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
June 5, 2026
Ticker
JBIO
Accession
0001193125-26-259586
Boardroom Alpha · Filing insights

Jade Biosciences reschedules its online 2026 annual meeting to 2:30 p.m. PT on June 9, 2026; registration required.

About Jade Biosciences Inc
Market cap
$1.4B
1Y TSR
+190.7%
3Y TSR
−63.1%
Board grade
C+
Sector
Healthcare
CEO
Tom Frohlich
Last annual meeting: Jun 9, 2026 · View full Jade Biosciences Inc profile →
DEFA14A
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 14A

SCHEDULE 14A INFORMATION

PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

SECURITIES EXCHANGE ACT OF 1934

(Amendment No. )

 

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

Jade Biosciences, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required

 

Fee paid previously with preliminary materials

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 
 


LOGO

Important Notice Regarding Time Change of 2026 Annual Meeting of Stockholders

The following Notice of Time Change relates to the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Jade Biosciences, Inc. (the “Company”) to be conducted solely online via live webcast as set forth in the proxy statement of the Company, dated April 28, 2026, previously furnished to stockholders of the Company in connection with the solicitation of proxies by the board of directors of the Company for use at the Annual Meeting. This supplement is being filed with the Securities and Exchange Commission on June 5, 2026.

The Following Notice Supplements and Should be Read in Conjunction with the Proxy Statement

Notice of Time Change of 2026 Annual Meeting of Stockholders

 

New Meeting Time: 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time
Meeting Date:    Tuesday, June 9, 2026
Meeting Place:    www.proxydocs.com/JBIO
Record Date:    April 17, 2026

To Our Stockholders:

Jade Biosciences, Inc. (the “Company”, or “our”) has announced that the time of the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) has been postponed to later the same day for administrative purposes. The Annual Meeting, which was originally scheduled to be held on Tuesday, June 9, 2026 at 9:00 a.m. Pacific Time / 12:00 p.m. Eastern Time, will now be held the same day at 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time.

As previously announced, the Annual Meeting will be a completely virtual meeting, which will be conducted via live webcast. As previously described in our proxy materials for the Annual Meeting, you must register to attend the Annual Meeting at www.proxydocs.com/JBIO by 9:00a.m. Pacific Time / 12:00 p.m. Eastern Time on June 7, 2026. Stockholders will need their unique control number which appears on your proxy card, Notice of Internet Availability of Proxy Materials or voting instruction form and the instructions that accompanied the proxy materials. In the event that you do not have a control number, please contact your broker, bank, or other agent as soon as possible, so that you can be provided with a control number and gain access to the meeting. To attend the Annual Meeting, access the website www.proxydocs.com/JBIO and enter the control number from your proxy card, Notice of Internet Availability of Proxy Materials or voting instruction form.

All other information and instructions included in our Notice of Annual Meeting dated April 28, 2026 and our proxy card and proxy statement for the Annual Meeting remain unchanged, including the record date for the Annual Meeting, which remains April 17, 2026. Stockholders who have already submitted their proxies will not need to submit a new proxy. Stockholders who wish to revoke a previously submitted proxy may do so by following the instructions provided in our proxy statement.


Your vote is important. Please vote your shares whether or not you plan to attend the virtual Annual Meeting. Each stockholder is urged to vote and submit their proxy in advance of the Annual Meeting using one of the methods described in our proxy materials for the Annual Meeting. You may view our proxy materials by visiting www.proxydocs.com/JBIO.

By Order of the Board of Directors,

 

LOGO

Elizabeth Balta

Chief Legal Officer and Corporate Secretary

June 5, 2026

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Jade Biosciences Inc (JBIO)

Reference

Frequently asked questions

When did Jade Biosciences Inc file this DEFA14A?
Jade Biosciences Inc (JBIO) filed this Additional Proxy Materials (DEFA14A) with the SEC on June 5, 2026. The accession number assigned by EDGAR is 0001193125-26-259586.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Jade Biosciences reschedules its online 2026 annual meeting to 2:30 p.m. PT on June 9, 2026; registration required. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Jade Biosciences Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Jade Biosciences Inc has filed under CIK 1798749, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer